Repository logo
 
Publication

First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID) : a report of 2 cases

dc.contributor.authorMarkert, M. L.
dc.contributor.authorMarques, J. G.
dc.contributor.authorNeven, B.
dc.contributor.authorDevlin, B. H.
dc.contributor.authorMcCarthy, E. A.
dc.contributor.authorChinn, I. K.
dc.contributor.authorAlbuquerque, A. S.
dc.contributor.authorSilva, S. L.
dc.contributor.authorPignata, C.
dc.contributor.authorde Saint Basile, G.
dc.contributor.authorVictorino, R. M.
dc.contributor.authorPicard, C.
dc.contributor.authorDebre, M.
dc.contributor.authorMahlaoui, N.
dc.contributor.authorFischer, A.
dc.contributor.authorSousa, A. E.
dc.date.accessioned2014-08-26T13:52:31Z
dc.date.available2014-08-26T13:52:31Z
dc.date.issued2010
dc.descriptionConflict-of-interest disclosure: M.L.M. receives funding from the NIH and the FDA and has a patent pending for culture conditions for thymus tissue for transplantation. B.H.D. and I.K.C. receive funding from the NIH, and E.A.M. receives funding from the NIH and the FDA. The remaining authors declare no competing financial interests.por
dc.description© 2011 by The American Society of Hematologypor
dc.description.abstractFOXN1 deficiency is a primary immunodeficiency characterized by athymia, alopecia totalis, and nail dystrophy. Two infants with FOXN1 deficiency were transplanted with cultured postnatal thymus tissue. Subject 1 presented with disseminated Bacillus Calmette-Guérin infection and oligoclonal T cells with no naive markers. Subject 2 had respiratory failure, human herpes virus 6 infection, cytopenias, and no circulating T cells. The subjects were given thymus transplants at 14 and 9 months of life, respectively. Subject 1 received immunosuppression before and for 10 months after transplantation. With follow up of 4.9 and 2.9 years, subjects 1 and 2 are well without infectious complications. The pretransplantation mycobacterial disease in subject 1 and cytopenias in subject 2 resolved. Subject 2 developed autoimmune thyroid disease 1.6 years after transplantation. Both subjects developed functional immunity. Subjects 1 and 2 have 1053/mm(3) and 1232/mm(3) CD3(+) cells, 647/mm(3) and 868/mm(3) CD4(+) T cells, 213/mm(3) and 425/mm(3) naive CD4(+) T cells, and 10 200 and 5700 T-cell receptor rearrangement excision circles per 100 000 CD3(+) cells, respectively. They have normal CD4 T-cell receptor β variable repertoires. Both subjects developed antigen-specific proliferative responses and have discontinued immunoglobulin replacement. In summary, thymus transplantation led to T-cell reconstitution and function in these FOXN1 deficient infants.por
dc.description.sponsorshipFunding sources included National Institutes of Health (NIH; grant nos. R01AI47040 and R01AI54843 to M.L.M. and M01RR30 NCRR, Clinical Research, to Duke University) and grants from “Fundação para a Ciênia e a Tecnologia” (FCT) and “Programa Operacional Ciêcia e Inovação 010” (POCI2010) PIC/83068 to R.M.V. and PTDC/66248 to A.E.S. A.S.A. received a scholarship from FCT. Thymus transplantation for subjects 1 and 2 was financially supported by the Portuguese and French national health services, respectively. M.L.M. is a member of the Duke Comprehensive Cancer Center.por
dc.identifier.citationBlood, 13 January 2011, Volume 117, Number 2por
dc.identifier.issn0006-4971
dc.identifier.urihttp://dx.doi.org/10.1182/blood-2010-06-292490
dc.identifier.urihttp://hdl.handle.net/10451/11736
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherThe American Society of Hematologypor
dc.titleFirst use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID) : a report of 2 casespor
dc.typejournal article
dspace.entity.typePublication
rcaap.rightsclosedAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
First_use_of_thymus_transplantation.pdf
Size:
874.5 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description: